A study testing whether an investigational medicine (KAI-9531) from Kailera can help with weight.
What this means for you
- Who can join
- Adults 18+, have obesity, BMI 35+.
- What you take
- KAI-9531, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 2.3 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Obesity.
Full scientific study title: Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do No.
Who can join
Adults 18+, have obesity, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- BMI >=35 kilograms per square meter (kg/m^2).
- History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months.
Key exclusion criteria
- Current diagnosis or history of diabetes mellitus.
- Started medications within 3 months prior to Screening that may cause significant weight gain, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, and mood stabilizers.
- Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.
- Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
- Uncontrolled hypertension or unstable cardiovascular disease.
Where this study is enrolling
This trial has 25 sites across 19 states. Contact a site coordinator directly to start screening.
Arizona2 sites
- Kailera Clinical SiteGlendale, Arizona
- Kailera Clinical SitePhoenix, Arizona
Arkansas1 site
- Kailera Clinical SiteLittle Rock, Arkansas
California2 sites
- Kailera Clinical SiteNorthridge, California
- Kailera Clinical SiteOceanside, California
Connecticut2 sites
- Kailera Clinical SiteHamden, Connecticut
- Kailera Clinical SiteStamford, Connecticut
Florida1 site
- Kailera Clinical SiteOrange City, Florida
Georgia1 site
- Kailera Clinical SiteAlbany, Georgia
Illinois1 site
- Kailera Clinical SiteChicago, Illinois
Kansas1 site
- Kailera Clinical SiteNewton, Kansas
Louisiana1 site
- Kailera Clinical SiteShreveport, Louisiana
Michigan1 site
- Kailera Clinical SiteFarmington Hills, Michigan
Montana1 site
- Kailera Clinical SiteMissoula, Montana
Nevada1 site
- Kailera Clinical SiteLas Vegas, Nevada
New York1 site
- Kailera Clinical SiteAlbany, New York
North Carolina1 site
- Kailera Clinical SiteMorehead City, North Carolina
Oklahoma1 site
- Kailera Clinical SiteNorman, Oklahoma
Rhode Island1 site
- Kailera Clinical SiteEast Greenwich, Rhode Island
South Carolina2 sites
- Kailera Clinical SiteNorth Charleston, South Carolina
- Kailera Clinical SiteSpartanburg, South Carolina
Texas2 sites
- Kailera Clinical SiteBrownsville, Texas
- Kailera Clinical SiteSan Antonio, Texas
Virginia2 sites
- Kailera Clinical SiteManassas, Virginia
- Kailera Clinical SiteRichmond, Virginia
Timeline
Started enrolling: 2025-12-30. Expected completion: 2028-04-17. Last updated on ClinicalTrials.gov: 2026-04-30.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
